CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Identifieur interne : 001639 ( Main/Corpus ); précédent : 001638; suivant : 001640CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Auteurs : Tycho Baumann ; Julio Delgado ; Emili MontserratSource :
- Leukemia [ 1476-5551 ] ; 2020.
English descriptors
- KwdEn :
- Age Factors (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antineoplastic Agents (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (pathogenicity), Biomarkers (blood), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (virology), Disease Progression (MeSH), Female (MeSH), Ferritins (metabolism), Fibrin Fibrinogen Degradation Products (metabolism), Humans (MeSH), Hydroxychloroquine (therapeutic use), Leukemia, Lymphocytic, Chronic, B-Cell (complications), Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Leukemia, Lymphocytic, Chronic, B-Cell (epidemiology), Lymphopenia (complications), Lymphopenia (drug therapy), Lymphopenia (epidemiology), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), Prevalence (MeSH), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (therapeutic use), Pyrimidines (therapeutic use), SARS-CoV-2 (MeSH), Spain (epidemiology), Survival Analysis (MeSH).
- MESH :
- chemical , blood : Biomarkers.
- chemical , metabolism : Ferritins, Fibrin Fibrinogen Degradation Products.
- chemical , therapeutic use : Antineoplastic Agents, Antiviral Agents, Hydroxychloroquine, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines.
- geographic , epidemiology : Spain.
- complications : Coronavirus Infections, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphopenia, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphopenia, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphopenia, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Age Factors, Aged, Aged, 80 and over, COVID-19, Disease Progression, Female, Humans, Male, Middle Aged, Pandemics, Prevalence, SARS-CoV-2, Survival Analysis.
DOI: 10.1038/s41375-020-0870-5
PubMed: 32433507
PubMed Central: PMC7237061
Links to Exploration step
pubmed:32433507Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.</title><author><name sortKey="Baumann, Tycho" sort="Baumann, Tycho" uniqKey="Baumann T" first="Tycho" last="Baumann">Tycho Baumann</name><affiliation><nlm:affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Delgado, Julio" sort="Delgado, Julio" uniqKey="Delgado J" first="Julio" last="Delgado">Julio Delgado</name><affiliation><nlm:affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Montserrat, Emili" sort="Montserrat, Emili" uniqKey="Montserrat E" first="Emili" last="Montserrat">Emili Montserrat</name><affiliation><nlm:affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain. emontse@clinic.cat.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32433507</idno><idno type="pmid">32433507</idno><idno type="doi">10.1038/s41375-020-0870-5</idno><idno type="pmc">PMC7237061</idno><idno type="wicri:Area/Main/Corpus">001639</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001639</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.</title><author><name sortKey="Baumann, Tycho" sort="Baumann, Tycho" uniqKey="Baumann T" first="Tycho" last="Baumann">Tycho Baumann</name><affiliation><nlm:affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Delgado, Julio" sort="Delgado, Julio" uniqKey="Delgado J" first="Julio" last="Delgado">Julio Delgado</name><affiliation><nlm:affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Montserrat, Emili" sort="Montserrat, Emili" uniqKey="Montserrat E" first="Emili" last="Montserrat">Emili Montserrat</name><affiliation><nlm:affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain. emontse@clinic.cat.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="eISSN">1476-5551</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (pathogenicity)</term><term>Biomarkers (blood)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (virology)</term><term>Disease Progression (MeSH)</term><term>Female (MeSH)</term><term>Ferritins (metabolism)</term><term>Fibrin Fibrinogen Degradation Products (metabolism)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (complications)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (epidemiology)</term><term>Lymphopenia (complications)</term><term>Lymphopenia (drug therapy)</term><term>Lymphopenia (epidemiology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (virology)</term><term>Prevalence (MeSH)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (therapeutic use)</term><term>Pyrimidines (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term><term>Spain (epidemiology)</term><term>Survival Analysis (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Ferritins</term><term>Fibrin Fibrinogen Degradation Products</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Leukemia, Lymphocytic, Chronic, B-Cell</term><term>Lymphopenia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Leukemia, Lymphocytic, Chronic, B-Cell</term><term>Lymphopenia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Leukemia, Lymphocytic, Chronic, B-Cell</term><term>Lymphopenia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>COVID-19</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Prevalence</term><term>SARS-CoV-2</term><term>Survival Analysis</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32433507</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.</ArticleTitle><Pagination><MedlinePgn>1954-1956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41375-020-0870-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Tycho</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montserrat</LastName><ForeName>Emili</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hospital Clinic University of Barcelona, Barcelona, Spain. emontse@clinic.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical><Chemical><RegistryNumber>1X70OSD4VX</RegistryNumber><NameOfSubstance UI="C551803">ibrutinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-73-2</RegistryNumber><NameOfSubstance UI="D005293">Ferritins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Haematol. 2020 Aug;190(4):e187-e189</RefSource><PMID Version="1">32557555</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Leukemia. 2020 Sep;34(9):2531-2532</RefSource><PMID Version="1">32753689</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32433507</ArticleId><ArticleId IdType="doi">10.1038/s41375-020-0870-5</ArticleId><ArticleId IdType="pii">10.1038/s41375-020-0870-5</ArticleId><ArticleId IdType="pmc">PMC7237061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . Accessed 5 May 2020.</Citation></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId></ArticleIdList></Reference><Reference><Citation>https://seer.cancer.gov/statfacts/html/clyl.html . Accessed 5 May 2020.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Oncol. 2020;395:1054–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VM, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020. https://doi.org/10.1016/j.cell.2020.04.035 .</Citation></Reference><Reference><Citation>Weber ANR, Bittner Z, Liu X, Dang T-M, Radstac, Ph, Brunner CI. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.</Citation></Reference><Reference><Citation>Treon S, Castillo J, Skarbnik A, Soumerai J, Ghobrial I, Guerra ML, et al. The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood 2020. https://doi.org/10.1182/blood.2020006288 .</Citation></Reference><Reference><Citation>Emani A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Academic Emerg Med. 2020;8:e35.</Citation></Reference><Reference><Citation>CDC COVID-19 Response Team. MMWR 2020;69:382–286.</Citation></Reference><Reference><Citation>ASH recommendations (endorsed by ERIC/EHA). 2020. https://www.hematology.org/covid-19/covid-19-and-cll .</Citation></Reference><Reference><Citation>von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, EHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases. Leukemia. (in press).</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001639 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001639 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32433507
|texte= CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32433507" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |